Canadian Solar Inc. (NASDAQ:CSIQ) raises fund to support development of pipeline projects and take the advantage of increasing opportunities. The Company has flexible balance sheet with strong cash flow position which help the Company to fund late-stage solar projects. As of December 31, 2013, Canadian Solar has a cash balance of $679.4 million and external borrowings of $201.9 million only for utility-scale solar power projects. It includes both short-term borrowings and log-term debt. Canadian Solar Inc. (NASDAQ:CSIQ), shares after opening at $25.75 moved to $27.41 on last trade day and at the end of the day closed at $24.99. Company price to sales ratio in past twelve months was calculated as 0.81 and price to cash ratio as 5.89. Canadian Solar Inc. (NASDAQ:CSIQ), showed a negative weekly performance of 19.34%.
Exelixis, Inc. (NASDAQ:EXEL)’s shares dropped 1.65% to $3.50. The company on Mar. 25 announced that the Independent Data Monitoring Committee (IDMC) notified the company that a planned interim analysis of the COMET-1 phase 3 pivotal trial has been completed, and that the IDMC recommended the trial proceed to its final analysis. Exelixis continues to anticipate top-line data from COMET-1 in 2014. COMET-1 is a randomized, double-blind, controlled trial designed to enroll 960 patients with mCRPC who have progressed after treatment with docetaxel, abiraterone and/or enzalutamide. All patients in the trial have bone metastases and there is no limit to the number or type of prior treatments. Exelixis, Inc. (NASDAQ:EXEL), shares fell 5.34% in last trading session and ended the day on $3.37. Exelixis, Inc. (NASDAQ:EXEL), return on equity ratio is recorded as -150.50% and its return on assets is -42.00%. Exelixis, Inc. (NASDAQ:EXEL), yearly performance is -32.87%.
On March 224, 2014, Horizon Pharma Inc (NASDAQ:HZNP) and Vidara agreed to $660 million merger deal. This will see Horizon move its headquarters to Ireland where Vidara is based. However, the chief executive of the combined company will be based at the North America headquarters. Horizon Pharma Inc (NASDAQ:HZNP), shares moved down 7.89% in last trading session and was closed at $12.02, while trading in range of $ 11.86 – 13.18. Horizon Pharma Inc (NASDAQ:HZNP), year to date (YTD) performance is 57.74%.
Barclays initiated coverage on shares of JinkoSolar Holding Co. (NYSE:JKS) in a research report sent to investors on Monday morning,Analyst Ratings Network reports. The firm issued an overweight rating and a $51.00 price target on the stock JinkoSolar Holding Co., Ltd. (NYSE:JKS), weekly performance is -15.21%. On last trading day company shares ended up $25.43. JinkoSolar Holding Co., Ltd. (NYSE:JKS), distance from 50-day simple moving average (SMA50) is -16.87%. Analysts mean target Price for the company is $43.00.
Leave a Reply